|1.||Belardinelli, Luiz: 3 articles (12/2012 - 08/2006)|
|2.||Zeng, Dewan: 3 articles (12/2012 - 08/2006)|
|3.||Zhong, Hongyan: 3 articles (12/2012 - 08/2006)|
|4.||Van Tassell, Benjamin W: 1 article (12/2012)|
|5.||Mezzaroma, Eleonora: 1 article (12/2012)|
|6.||Abbate, Antonio: 1 article (12/2012)|
|7.||Voelkel, Norbert F: 1 article (12/2012)|
|8.||Toldo, Stefano: 1 article (12/2012)|
|9.||Kannan, Harsha: 1 article (12/2012)|
|10.||Ham, J: 1 article (12/2008)|
|1.||Asthma (Bronchial Asthma)
12/01/2008 - "Nevertheless several A2b receptor antagonists are being developed for therapeutic intervention and these are either at the preclinical stage or in phase I clinical trials as is the case for CVT-6883 for asthma."
03/01/2007 - "The present study describes the effects of a selective A(2B) AR antagonist, CVT-6883 [3-ethyl-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-3,7-dihydropurine-2,6-dione], on airway reactivity and inflammation in an allergic mouse model of asthma. "
08/01/2006 - "To investigate the role of the A2BAR in vivo, ADA-deficient mice were treated with the selective A2BAR antagonist CVT-6883, and pulmonary inflammation, fibrosis, and airspace integrity were assessed. "
08/01/2006 - "In addition, treatment with CVT-6883 attenuated pulmonary inflammation and fibrosis in wild-type mice subjected to bleomycin-induced lung injury. "